Clinical Trials
10 trialsNCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04508400 2024-01-09
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Sun Yat-sen University
Phase 2 Completed
NCT02991456 2023-07-11
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Duke University
Phase 2 Completed
NCT03572829 2020-07-15
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
ChineseAMS
Phase 2 Completed
NCT01450826 2018-06-26
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Phase 2 Completed
NCT00795769 2017-05-23
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00003817 2015-10-15
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
University of Rochester
Phase 2 Completed
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01031498 2012-08-07
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00169572 2010-05-10
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
Phase 2 Completed